Diazepinone HBV capsid assembly modulators.
Kuduk, S.D., DeRatt, L.G., Stoops, B., Shaffer, P., Lam, A.M., Espiritu, C., Vogel, R., Lau, V., Flores, O.A., Hartman, G.D.(2022) Bioorg Med Chem Lett 72: 128823
- PubMed: 35644301 
- DOI: https://doi.org/10.1016/j.bmcl.2022.128823
- Primary Citation of Related Structures:  
8GIH - PubMed Abstract: 
The HBV capsid core protein serves a number of important functions in the viral life cycle enabling chronic HBV infection to persist, and therefore is a promising drug target. Interfering with capsid assembly has shown efficacy in clinical trials with small molecule capsid assembly modulators (CAMs). Herein is described the further optimization of a progressive series of diazepinone HBV CAMs.
Organizational Affiliation: 
Janssen Research and Development, 1400 McKean Road, Spring House, PA 19477, United States. Electronic address: skuduk@its.jnj.com.